4.3.4 共病性抑郁 综合医院患者躯体疾病伴发或共病焦虑、抑郁较为常见,如脑卒中、帕金森综合征、老年性痴呆、冠心病、糖尿病、慢性阻塞性肺疾病、恶性肿瘤等。部分心血管药物(如可乐定、利舍平、β受体阻断药)、中枢神经系统药物(如巴比妥类、苯二氮类、苯妥英)、激素类药物(如皮质醇激素、雌激素、黄体酮)及吲哚美辛、干扰素、麻醉剂等在治疗过程中也可引起抑郁症。原发疾病或药物可导致抑郁症,反之,持续存在的抑郁症又影响原发疾病的预后与转归,二者相互促进,关系复杂。临床工作中应注意识别和区分原发疾病本身表现和共病性抑郁,积极应用量表综合评估,这点已成为国内专家共识[19]。症状较轻者可给予健康教育和心理支持治疗;中重度抑郁症建议精神科会诊或转诊。共病性抑郁症治疗关键在于早期识别和介入,积极治疗原发病及去除可能心理、药物因素。抗抑郁症药物共病性抑郁症患者与一般抑郁人群无明显差别,但应注意药物相互作用及不良反应。我国专家共识[19]建议,卒中后抑郁症可考虑选择西酞普兰、舍曲林、艾司西酞普兰等SSRIs类及TCAs中的阿米替林等药物;痴呆患者可选择抗胆碱能作用小的药物,如安非他酮、氟西汀、舍曲林、曲唑酮;帕金森综合征患者可考虑选择帕罗西汀及文拉法辛,不加重帕金森综合征的运动症状;合并心血管疾病可选择SSRIs、SNRIs、安非他酮等,但需注意QT间期延长风险;合并糖尿病患者可选择能减少对胰岛素抵抗的SSRIs;癌症患者可以选择疗效较肯定的SSRIs和SNRIs;躯体疼痛症状明显者,建议优先选择对疼痛疗效好且不良反应小的SNRIs。
As clinicians, we routinely make critical decisions for our patients with depression. Because of the uncertainty of factors that affect diagnosis and treatment, clinicians may find an objective, quick measurement tool helpful. Measurementbased care (MBC) provides specific and objective information on which to base clinical decisions and should therefore enhance quality of care and treatment outcomes. (1-3) MBC rests on these assumptions. * Compared with general questions that are typically asked during a patient evaluation, specific measurements (administered by clinicians or self-reported by patients) provide more accurate information on which to establish a diagnosis, assess treatment outcomes, and modify treatments. * Patients who complete these measurement tests will better understand their disorder and treatment effects, which will enable them to better manage their depression. * Medical records that include the results of specific measurements will assist subsequent clinicians in understanding the results of prior treatments. * The routine use of the same measurements in practice and clinical research studies will help clinicians translate research findings into their own practices. * For most outpatients with depression, self-report methods are available that are free and that take little time and effort. Diagnostic measurements Researchers have used criterion-based diagnostic methods for years. After DSM-III was introduced in 1980, the Structured Clinical Interviews for DSM-III (SCID) (and later for DSMIV) were developed to obtain lifetime diagnoses. (4,5) Briefer structured interviews were then developed, including the Mini-International Neuropsychiatric Interview (MINI), which assesses only current diagnoses, and the MINI-Plus, which elicits information about current and past diagnoses. (6-8) The MINI takes 30 to 40 minutes to administer, while the MINI-Plus may take up to 60 minutes. Studies have shown that structured or semistructured interviews provide more accurate diagnoses than typical practice. For example, clinically rendered diagnoses were compared with those made based on SCID results. (9) Major diagnostic differences were found in 40% of outpatients with clinical diagnoses of schizophrenia or bipolar or major depressive disorders. In addition, when clinicians were provided with a diagnosis that was determined using SCID, they changed the chart diagnosis in a substantial proportion of cases and prescribed fewer medications. (10) Symptom measurements Once a diagnosis has been made and therapy has been initiated, the regimen must often be modified because of intolerance, adverse effects, or other less-than-desirable symptomatic outcomes. Medication and somatic therapies are typically aimed at treating symptoms, but psychotherapy and disease self-management may also address other aspects of treatment (eg, medication adherence, social/occupational function, self-esteem). The Texas Medication Algorithm Project (TMAP) and the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) studies showed that diligent assessment of symptoms and adverse effects enhances outcomes. (11-14) The goal of therapy for depression is symptom remission and, ultimately, sustained remission and functional recovery. (15) Most patients require more than 1 treatment revision (eg, altered dosage, treatment, or delivery). When implementing guideline-driven or evidencebased care, initial treatment is continued until remission or maximal symptom improvement is obtained or until the patient cannot tolerate the regimen. Thereafter, the dosage or type of treatment may...
抑郁症是一种常见的心境障碍,可由多种原因引起,以显著而持久的情绪低落、愉快感缺失为核心症状。目前抑郁症的病因、发病机制尚不明确。一般认为,抑郁症的发病主要与生物化学因素如去甲肾上腺素(norepinephrine,NE)、5-羟色胺(5-hydroxytryptamine,5-HT)和多巴胺(dopamine,DA),遗传因素,社会与环境因素有关。多数病例有反复发作倾向,每次发作大部分可以缓解,部分患者可有残留症状或进展为慢性抑郁[1]。抑郁症除导致一系列生理、心理、社会功能障碍外,还存在潜在的高自杀风险,加重患者、家属及社会的负担。世界卫生组织(WHO)调查发现,全球抑郁症患者估计为3.22亿例,占世界人口的4.4%[2]。研究表明,抑郁症已经成为全世界最大的致残性疾病[3]。在全球疾病负担过重的疾病中,抑郁症疾病负担占社会总体经济成本的三分之一,预计到2030年将上升至世界疾病负担首位[4]。流行病学资料显示,中国人中有20%存在抑郁症状,其中7%为重度抑郁; 抑郁症占中国疾病负担的第2位,其中仅有不足10%抑郁症患者得到正规治疗[5]。 现就抑郁症的治疗进展综述如下。

张老师您好!我是刚刚读完渡过1的一名普通读者,因为我的一个朋友刚刚被诊断为精神分裂症,所以特别想了解精神类疾病和各种情况,尤其是如何治疗。读了您的书收获颇丰,只是对于朋友在医院的诊断还是有些疑虑,想请教您。 症状:注意力不集中,上课会游离,能听到别人(认识但不熟悉)说她的坏话(幻听),尤其是在安静的时候,看到别人聊天总觉得是在说自己,感觉不自在,总感觉有人在监视自己,在家里感觉不安全,在朋友家里待过半天觉得挺舒服。最近一直闹着说要转学,这样到了陌生的学校,同学就不会说她的坏话了,经常对家长提一些比较高的要求,比如买车、换大房子等等。有过一次轻生的念头,觉得每天被人监视的生活太累了,想结束痛苦的生活。(她还是个学生,一直以来较为内向,学习成绩较好,父亲长期不在家里,母亲对她学习要求严格) 通过网上查询和学习您的著作,感觉她的症状更像抑郁症,而不是精神分裂症。我也是担心医院误诊,造成耽误后期治疗的不良后果,请您答疑解惑,谢谢了。
×